Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companyâs lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy. Source
No articles found.
Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company fo...
Amarin Corporation plc. is a rapidly growing, i...
We are a late stage biopharmaceutical company focused on the development and comme...
We are a late stage biopharmaceutical company f...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
Fibrocell is a cell and gene therapy company focused on improving the lives of peo...
Fibrocell is a cell and gene therapy company fo...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse p...
Oncternal Therapeutics is a clinical-stage onco...
PTC is a science-led, global biopharmaceutical company focused on the discovery, d...
PTC is a science-led, global biopharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.